Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2425 of 2873 entries
View as:

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01946152 Org: User:
Start: 03/05/14 End: 03/18/20 Due: 03/18/21

Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05055843 Org: User:
Start: 08/10/21 End: 01/31/27 Due: 01/31/28

Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix

Phase: N/A Priority: Normal
NCT ID: NCT02206048 Org: User:
Start: 10/02/15 End: 04/21/21 Due: 04/21/22

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Phase: N/A Priority: Normal
NCT ID: NCT02208375 Org: User:
Start: 11/11/14 End: 12/30/25 Due: 12/30/26

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03531645 Org: User:
Start: 08/13/19 End: 09/30/25 Due: 09/30/26

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04550442 Org: User:
Start: 09/04/20 End: 08/31/25 Due: 08/31/26

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05017025 Org: User:
Start: 02/17/22 End: 06/30/26 Due: 06/30/27

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Phase: N/A Priority: Normal
NCT ID: NCT01875237 Org: User:
Start: 12/27/13 End: 03/07/17 Due: 03/07/18

Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00509600 Org: User:
Start: 09/30/04 End: 04/30/09 Due: 04/30/10

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04493164 Org: User:
Start: 12/30/20 End: 06/01/26 Due: 06/01/27

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00500110 Org: User:
Start: 06/30/03 End: 02/28/10 Due: 02/28/11

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Phase: N/A Priority: Normal
NCT ID: NCT01927744 Org: User:
Start: 12/16/13 End: 01/06/25 Due: 01/06/26

Exercise Program for Adolescents and Young Adults With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00502749 Org: User:
Start: 02/28/03 End: 10/31/10 Due: 10/31/11

Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)

Phase: N/A Priority: Normal
NCT ID: NCT00811031 Org: User:
Start: - End: - Due: -

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01718743 Org: User:
Start: 12/03/12 End: 04/12/23 Due: 04/12/24

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02529813 Org: User:
Start: 12/16/15 End: 11/08/21 Due: 11/08/22

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Phase: N/A Priority: Normal
NCT ID: NCT00816114 Org: User:
Start: 06/08/05 End: 04/30/30 Due: 04/30/31

A Randomized Trial Comparing a Ventilatory Strategy To Prevent Atelectasis Versus a Lateral Decubitus Strategy During Robotic Bronchoscopy (VESPA vs. LADS Trial)

Phase: N/A Priority: Normal
NCT ID: NCT05714033 Org: User:
Start: 02/10/23 End: 09/14/32 Due: 09/14/33

Simple Versus Radical Hysterectomy for Stage I Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00506376 Org: User:
Start: 01/31/03 End: 02/29/16 Due: 02/28/17

Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment

Phase: N/A Priority: Normal
NCT ID: NCT05005936 Org: User:
Start: 11/29/21 End: 11/29/21 Due: 11/29/22

Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

Phase: N/A Priority: Normal
NCT ID: NCT01396499 Org: User:
Start: 07/31/12 End: 10/31/16 Due: 10/31/17

Time From Onset of Fever to Administration of Antibiotics in Neutropenic Fever Patients

Phase: N/A Priority: Normal
NCT ID: NCT03968328 Org: User:
Start: 06/19/15 End: 01/17/23 Due: 01/17/24

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Phase: N/A Priority: Normal
NCT ID: NCT01110876 Org: User:
Start: 06/30/11 End: 07/31/14 Due: 07/31/15

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03620201 Org: User:
Start: 08/03/18 End: 10/18/24 Due: 10/18/25

Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01939730 Org: User:
Start: 08/31/99 End: 09/30/13 Due: 09/30/14